NCT06009276

Brief Summary

The purpose of the study is to determine associations between fitness status, bacteria in the mouth, and the blood flow to muscle. This study is trying to find out if fitness status impacts the bacteria that are present in the oral microbiome (environment in the mouth) or the ability of the body to send blood to the skeletal muscle. Participants will complete all or some of the following:

  • A mouth swab to assess the bacteria in their mouths.
  • Produce a saliva sample into a tube.
  • Cycle on a bike until you reach maximum effort.
  • Undergo blood draws
  • Wear a 24-hour non-invasive device that monitors blood pressure.
  • Drink 70mL (1/3 of a cup) of concentrated beetroot juice once

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
7mo left

Started Aug 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Aug 2023Dec 2026

First Submitted

Initial submission to the registry

August 18, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 24, 2023

Completed
6 days until next milestone

Study Start

First participant enrolled

August 30, 2023

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

December 24, 2025

Status Verified

December 1, 2025

Enrollment Period

3.3 years

First QC Date

August 18, 2023

Last Update Submit

December 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Oral Nitrate Reducing Capacity

    Assessment of the oral microbiome's ability to reduce nitrate to nitrite. This will be measured through a swab on the dorsal surface of the tongue, an unstimulated saliva sample, and a rinse of a standard nitrate solution.

    Baseline, 4-weeks, 12-weeks, 6-months

Secondary Outcomes (1)

  • Aerobic Capacity

    Baseline, 4-weeks, 12-weeks, 6-months

Other Outcomes (10)

  • Peripheral and Central Blood Pressures

    Baseline, 4-weeks, 12-weeks, 6-months

  • 24-hour ambulatory blood pressure

    Baseline, 4-weeks, 12-weeks, 6-months

  • Flow-Mediated Dilation

    Baseline, 4-weeks, 12-weeks, 6-months

  • +7 more other outcomes

Study Arms (3)

Heart Failure

Patients diagnosed with Heart Failure (HFrEF and HFpEF). Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.

Peripheral Artery Disease

Patients diagnosed with Peripheral Artery Disease (PAD). Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.

Healthy Controls

Individuals that are not diagnosed with cardiovascular disease. Oral microbiome will be analyzed through tongue swabs, saliva samples, and a saliva rinse. Patients will undergo a maximal exercise test, blood draws, and vascular testing. Patients will have the option to participate in a supplementation assessment with concentrated beetroot juice.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The population will include healthy individuals over the age of 18 years of either sex, or individuals with cardiovascular disease (heart failure, peripheral artery disease).

You may qualify if:

  • Subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
  • Subjects may be of either sex with age 18 years.

You may not qualify if:

  • Oral antibiotic use within previous four weeks
  • Oral disease or poor oral health as determined by the Oral Health Questionnaire
  • Using an antibacterial mouthwash or a mouthwash containing chlorhexidine and unwilling to discontinue use
  • Tobacco smokers
  • Pregnant or lactating females
  • Hypersensitivity to any ultrasound contrast agent
  • Inability to perform exercise
  • Unable to communicate effectively in English to the study team.
  • Diagnosis of chronic renal failure (GFR \< 60 ml/min/1.73m)
  • Subjects taking nitroglycerine (or inorganic nitrates), PDE-5 inhibitors (ex: Cialis, Viagra), and xanthine oxidase inhibitors (ex: Allopurinol).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UVA Student Health and Wellness Building

Charlottesville, Virginia, 22903, United States

RECRUITING

MeSH Terms

Conditions

Heart Failure, SystolicHeart Failure, DiastolicPeripheral Arterial DiseaseOverweightObesity

Condition Hierarchy (Ancestors)

Heart FailureHeart DiseasesCardiovascular DiseasesAtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesPeripheral Vascular DiseasesOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Jason D Allen, PhD

    University of Virginia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Casey C Derella, PhD

CONTACT

Macy E Stahl, B.S.E.d

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Kinesiology

Study Record Dates

First Submitted

August 18, 2023

First Posted

August 24, 2023

Study Start

August 30, 2023

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

December 24, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations